GlassScriptPhysician profile
Rony Michael Alaniz
NPI 1669294237
$3,594.31
in general payments reported to CMS, 2019-2025
20 companies · $3,120 in 2025
The $3,120 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $474 · 2025: $3,120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,594.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $538.13 | 2024-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $500.76 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $451.16 | 2024-2025 | Jardiance |
| Axsome Therapeutics, INC. | $242.70 | 2024 | Auvelity |
| Pfizer INC. | $238.07 | 2025 | |
| Lilly USA, LLC | $233.21 | 2025 | Jardiance, Mounjaro |
| Alnylam Pharmaceuticals INC. | $189.29 | 2025 | Amvuttra |
| Scpharmaceuticals INC. | $175.93 | 2025 | |
| Medtronic, INC. | $164.91 | 2025 | Corevalve Evolut R, Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan |
| Novo Nordisk INC | $147.16 | 2025 | Ozempic |
| E.R. Squibb & Sons, L.L.C. | $123.19 | 2025 | Camzyos |
| Bridgebio Pharma, INC. | $115.49 | 2025 | Attruby |
| Biotronik INC. | $106.50 | 2025 | Amvia Edge, Biomonitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $102.26 | 2024-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $66.87 | 2025 | Wainua |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $65.34 | 2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $41.50 | 2025 | |
| Abbvie INC. | $35.70 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $30.80 | 2025 | Evkeeza |
| Tactile Systems Technology INC | $25.34 | 2025 | Flexitouch Plus, Nimbl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rony Alaniz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.